Werth Peter J.

SEC source: 0001493152-26-033961 · ownership.xml · derivative · entry 1

Werth Peter J. · CIK 0001883257 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2036-07-16

F1 · derivative.exercise_date: The option vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Cingulate Inc. 2027 annual meeting of stockholders.

SEC source: 0001493152-26-006027 · ownership.xml · derivative · entry 3

Werth Peter J. · CIK 0001883257 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Werth Family Investment Associates LLC

Disclosed balance after: 15,564

Underlying: Common Stock · 15,564 shares

Expires not disclosed

F1 · date: Common stock and warrants were acquired in the Issuer's private placement disclosed in the Current Report on Form 8-K filed with the SEC on January 28, 2026.

F3 · derivative.exercise_date: The warrant is exercisable upon the Issuer obtaining stockholder approval of the private placement, as required by the Nasdaq rules. The expiration date of the warrant is 36 months after the exercise date.

F3 · derivative.expiration_date: The warrant is exercisable upon the Issuer obtaining stockholder approval of the private placement, as required by the Nasdaq rules. The expiration date of the warrant is 36 months after the exercise date.

F2 · ownership.nature: Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001493152-26-006027 · ownership.xml · nonDerivative · entry 1

Werth Peter J. · CIK 0001883257 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Werth Family Investment Associates LLC

Disclosed balance after: 117,449

F1 · date: Common stock and warrants were acquired in the Issuer's private placement disclosed in the Current Report on Form 8-K filed with the SEC on January 28, 2026.

F2 · ownership.nature: Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001641172-25-016181 · ownership.xml · derivative · entry 1

Werth Peter J. · CIK 0001883257 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2035-06-20

F1 · derivative.exercise_date: The option vests on the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the Cingulate Inc. 2026 annual meeting of stockholders.

SEC source: 0001493152-24-023773 · ownership.xml · derivative · entry 2

Werth Peter J. · CIK 0001883257 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2034-06-12

F2 · derivative.exercise_date: The option vests on the one-year anniversary of the date of grant.

SEC source: 0001493152-24-023773 · ownership.xml · derivative · entry 1

Werth Peter J. · CIK 0001883257 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,926

Underlying: Common Stock · 6,926 shares

Expires 2034-03-04

F1 · date: The stock option grant was approved by Cingulate Inc.'s board of directors on March 4, 2024, subject to stockholder approval of Amendment No.1 to the Cingulate Inc. 2021 Omnibus Equity Incentive Plan (the "Amendment"). Cingulate's stockholders approved the Amendment on June 11, 2024.

F3 · price: The option was issued to the reporting person in lieu of cash retainer fees of $13,852.

F2 · derivative.exercise_date: The option vests on the one-year anniversary of the date of grant.

SEC source: 0001493152-24-014504 · ownership.xml · derivative · entry 5

Werth Peter J. · CIK 0001883257 · Director · 10% owner

Werth Family Investment Associates LLC · CIK 0001885004 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Werth Family Investment Associates LLC

Disclosed balance after: 0

Underlying: Common Stock · 694,096 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 687,043 of the pre-funded warrants were issued and immediately exercisable on January 25, 2024, and 7,053 of the pre-funded warrants were issued and immediately exercisable on March 25, 2024.

F3 · derivative.expiration_date: The pre-funded warrants have no expiration date.

F1 · ownership.nature: Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001493152-24-014504 · ownership.xml · derivative · entry 4

Werth Peter J. · CIK 0001883257 · Director · 10% owner

Werth Family Investment Associates LLC · CIK 0001885004 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Werth Family Investment Associates LLC

Disclosed balance after: 0

Underlying: Common Stock · 341,912 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The number of pre-funded warrants and shares and the exercise price reflect the 1-for-20 reverse stock split of the Issuer's issued and outstanding shares of common stock, which became effective on November 30, 2023.

F2 · shares: The number of pre-funded warrants and shares and the exercise price reflect the 1-for-20 reverse stock split of the Issuer's issued and outstanding shares of common stock, which became effective on November 30, 2023.

F3 · derivative.expiration_date: The pre-funded warrants have no expiration date.

F2 · derivative.underlying_shares: The number of pre-funded warrants and shares and the exercise price reflect the 1-for-20 reverse stock split of the Issuer's issued and outstanding shares of common stock, which became effective on November 30, 2023.

F1 · ownership.nature: Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001493152-24-014504 · ownership.xml · nonDerivative · entry 2

Werth Peter J. · CIK 0001883257 · Director · 10% owner

Werth Family Investment Associates LLC · CIK 0001885004 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Werth Family Investment Associates LLC

Disclosed balance after: 1,175,925

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001493152-24-014504 · ownership.xml · nonDerivative · entry 1

Werth Peter J. · CIK 0001883257 · Director · 10% owner

Werth Family Investment Associates LLC · CIK 0001885004 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Werth Family Investment Associates LLC

Disclosed balance after: 481,829

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001493152-24-011578 · ownership.xml · derivative · entry 1

Werth Peter J. · CIK 0001883257 · Director · 10% owner

Werth Family Investment Associates LLC · CIK 0001885004 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Werth Family Investment Associates LLC

Disclosed balance after: 694,096

Underlying: Common Stock · 7,053 shares

Expires not disclosed

F1 · kind: On January 25, 2024, the Issuer and Cingulate Therapeutics LLC ("CTx"), a wholly-owned subsidiary of the Issuer, entered into a Note Conversion Agreement with Werth Family Investment Associates LLC ("WFIA"), pursuant to which WFIA agreed to convert the remaining principal amount plus all accrued interest thereon (other than the Outstanding Interest (as defined below)), or $3,287,500, under the Amended and Restated Promissory Note, dated May 9, 2023 (the "Note"), that CTx issued to WFIA into pre-funded warrants to purchase 687,043 shares of common stock of the Issuer, at a conversion price per pre-funded warrant of $4.785. Due to a calculation error, $33,750 of interest (the "Outstanding Interest") on the remaining principal amount of the Note remained as of January 25, 2024. The Outstanding Interest was converted into additional pre-funded warrants to purchase 7,053 shares of common stock of the Issuer at a conversion price per pre-funded warrant of $4.785.

F1 · price: On January 25, 2024, the Issuer and Cingulate Therapeutics LLC ("CTx"), a wholly-owned subsidiary of the Issuer, entered into a Note Conversion Agreement with Werth Family Investment Associates LLC ("WFIA"), pursuant to which WFIA agreed to convert the remaining principal amount plus all accrued interest thereon (other than the Outstanding Interest (as defined below)), or $3,287,500, under the Amended and Restated Promissory Note, dated May 9, 2023 (the "Note"), that CTx issued to WFIA into pre-funded warrants to purchase 687,043 shares of common stock of the Issuer, at a conversion price per pre-funded warrant of $4.785. Due to a calculation error, $33,750 of interest (the "Outstanding Interest") on the remaining principal amount of the Note remained as of January 25, 2024. The Outstanding Interest was converted into additional pre-funded warrants to purchase 7,053 shares of common stock of the Issuer at a conversion price per pre-funded warrant of $4.785.

F2 · derivative.expiration_date: The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of common stock of the Issuer.

F3 · ownership.nature: Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001493152-24-009091 · ownership.xml · derivative · entry 1

Werth Peter J. · CIK 0001883257 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,824

Underlying: Common Stock · 1,824 shares

Expires 2034-03-04

F2 · price: The option was issued to the reporting person in lieu of cash retainer fees of $3,648.

F1 · derivative.exercise_date: The option vests on the one-year anniversary of the date of grant.

SEC source: 0001493152-24-004170 · ownership.xml · derivative · entry 1

Werth Peter J. · CIK 0001883257 · Director · 10% owner

Werth Family Investment Associates LLC · CIK 0001885004 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Werth Family Investment Associates LLC

Disclosed balance after: 687,043

Underlying: Common Stock · 687,043 shares

Expires not disclosed

F1 · kind: On January 25, 2024, the Issuer and Cingulate Therapeutics LLC ("CTx"), a wholly-owned subsidiary of the Issuer, entered into a Note Conversion Agreement with Werth Family Investment Associates LLC ("WFIA"), pursuant to which WFIA agreed to convert the remaining principal amount plus all accrued interest thereon, or $3,287,500, under the Amended and Restated Promissory Note, dated May 9, 2023, that CTx issued to WFIA into pre-funded warrants to purchase 687,043 shares of common stock of the Issuer, at a conversion price per pre-funded warrant of $4.785.

F1 · price: On January 25, 2024, the Issuer and Cingulate Therapeutics LLC ("CTx"), a wholly-owned subsidiary of the Issuer, entered into a Note Conversion Agreement with Werth Family Investment Associates LLC ("WFIA"), pursuant to which WFIA agreed to convert the remaining principal amount plus all accrued interest thereon, or $3,287,500, under the Amended and Restated Promissory Note, dated May 9, 2023, that CTx issued to WFIA into pre-funded warrants to purchase 687,043 shares of common stock of the Issuer, at a conversion price per pre-funded warrant of $4.785.

F2 · derivative.expiration_date: The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of common stock of the Issuer.

F3 · ownership.nature: Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001493152-23-032275 · ownership.xml · derivative · entry 1

Werth Peter J. · CIK 0001883257 · Director · 10% owner

Werth Family Investment Associates LLC · CIK 0001885004 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Werth Family Investment Associates LLC

Disclosed balance after: 6,838,235

Underlying: Common Stock · 6,838,235 shares

Expires not disclosed

F1 · kind: On August 9, 2022, Cingulate Therapeutics LLC ("CTx"), a wholly-owned subsidiary of the Issuer, issued a Promissory Note (the "Original Note") to Werth Family Investment Associates LLC ("WFIA") with a principal amount of $5,000,000 (the "Original Principal Amount"), and on May 9, 2023, CTx issued an Amended and Restated Promissory Note (the "A&R Note") increasing the principal amount under the Original Note by $3,000,000 to $8,000,000. On September 8, 2023, the Issuer and CTx entered into a Note Conversion Agreement (the "Note Conversion Agreement") with WFIA, pursuant to which WFIA agreed to convert the Original Principal Amount under the A&R Note plus all accrued interest thereon, or $5,812,500, into pre-funded warrants to purchase 6,838,235 shares of common stock of the Issuer, at a conversion price per pre-funded warrant of $0.85

F1 · price: On August 9, 2022, Cingulate Therapeutics LLC ("CTx"), a wholly-owned subsidiary of the Issuer, issued a Promissory Note (the "Original Note") to Werth Family Investment Associates LLC ("WFIA") with a principal amount of $5,000,000 (the "Original Principal Amount"), and on May 9, 2023, CTx issued an Amended and Restated Promissory Note (the "A&R Note") increasing the principal amount under the Original Note by $3,000,000 to $8,000,000. On September 8, 2023, the Issuer and CTx entered into a Note Conversion Agreement (the "Note Conversion Agreement") with WFIA, pursuant to which WFIA agreed to convert the Original Principal Amount under the A&R Note plus all accrued interest thereon, or $5,812,500, into pre-funded warrants to purchase 6,838,235 shares of common stock of the Issuer, at a conversion price per pre-funded warrant of $0.85

F2 · derivative.expiration_date: The pre-funded warrants have no expiration date and are exercisable immediately, to the extent that after giving effect to such exercise the reporting person and its affiliates would beneficially own, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, no more than 19.99% of the outstanding shares of Common Stock of the Issuer.

F3 · ownership.nature: Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001493152-23-028563 · ownership.xml · nonDerivative · entry 1

Werth Peter J. · CIK 0001883257 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Werth Family Investment Associates LLC

Disclosed balance after: 2,798,320

F1 · kind: The purchase was made in a private transaction with the Issuer that closed on August 11, 2023.

F2 · ownership.nature: Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001493152-23-021770 · ownership.xml · derivative · entry 1

Werth Peter J. · CIK 0001883257 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2033-06-15

F1 · derivative.exercise_date: The option vests on the one-year anniversary of the date of grant.

SEC source: 0001493152-22-035632 · ownership.xml · nonDerivative · entry 1

Werth Peter J. · CIK 0001883257 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Werth Family Investment Associates LLC

Disclosed balance after: 975,165

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9781 to $1.00 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth.

F2 · ownership.nature: Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001493152-22-025401 · ownership.xml · nonDerivative · entry 1

Werth Peter J. · CIK 0001883257 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Werth Family Investment Associates LLC

Disclosed balance after: 946,231

F1 · ownership.nature: Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001493152-22-007285 · ownership.xml · nonDerivative · entry 1

Werth Peter J. · CIK 0001883257 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Werth Family Investment Associates LLC

Disclosed balance after: 871,731

F1 · ownership.nature: Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001493152-22-005778 · ownership.xml · derivative · entry 1

Werth Peter J. · CIK 0001883257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,000

Underlying: Common Stock · 9,000 shares

Expires 2032-02-25

F1 · derivative.exercise_date: The option vests on the one-year anniversary of the date of grant.

SEC source: 0001493152-21-031458 · ownership.xml · derivative · entry 3

Werth Peter J. · CIK 0001883257 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Werth Family Investment Associates LLC

Disclosed balance after: 8,300

Underlying: Common Stock · 8,300 shares

Expires 2026-12-10

F1 · price: Werth Family Investment Associates LLC purchased 8,300 Units in the Issuer's initial public offering at $6.00 per Unit. Each Unit consists of one share of Common Stock and one warrant to purchase one share of Common Stock.

F2 · ownership.nature: Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001493152-21-031458 · ownership.xml · nonDerivative · entry 1

Werth Peter J. · CIK 0001883257 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Werth Family Investment Associates LLC

Disclosed balance after: 844,731

F1 · price: Werth Family Investment Associates LLC purchased 8,300 Units in the Issuer's initial public offering at $6.00 per Unit. Each Unit consists of one share of Common Stock and one warrant to purchase one share of Common Stock.

F2 · ownership.nature: Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0001493152-21-030995 · ownership.xml · derivative · entry 1

Werth Peter J. · CIK 0001883257 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,983

Underlying: Common Stock · 8,983 shares

Expires 2031-12-07

F1 · derivative.exercise_date: The option vests in four equal annual installments commencing on December 7, 2022.